Form 8-K - Current report:
SEC Accession No. 0000950170-24-067306
Filing Date
2024-05-31
Accepted
2024-05-31 16:07:52
Documents
11
Period of Report
2024-05-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20240529.htm   iXBRL 8-K 84938
  Complete submission text file 0000950170-24-067306.txt   196581

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20240529.xsd EX-101.SCH 23892
14 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20240529_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 241009701
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)